Comparison of two combined antiretroviral treatment regimens in the management of HIV in pregnancy: an observational study

References

• Kourtis AP, Lee FK, Abrams EJ, et al. Mother-to-child transmission of HIV-1: timing and implications for prevention. Lancet Infect Dis. 2006;6(11):726–732.
   PubMed Web of Science ®Google Scholar
• Barral MF, de Oliveira GR, Lobato RC, et al. Risk factors of HIV-1 vertical transmission (VT) and the influence of antiretroviral therapy (ART) in pregnancy outcome. Rev Inst Med Trop S Paulo. 2014;56(2):133–138.
   PubMed Web of Science ®Google Scholar
• Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331(18):1173–1180.
   PubMed Web of Science ®Google Scholar
• The International Perinatal HIV Group, Andiman W, Bryson Y, et al. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1-a meta-analysis of 15 prospective cohort studies. N Engl J Med. 1999;340(13):977–987.
   PubMed Web of Science ®Google Scholar
• Townsend CL, Byrne L, Cortina-Borja M, et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011. AIDS. 2014;28(7):1049–1057.
   PubMed Web of Science ®Google Scholar
• Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med. 1999;341(6):385–393.
   PubMed Web of Science ®Google Scholar
• Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med. 1999;341(6):394–402.
   PubMed Web of Science ®Google Scholar
• Briand N, Warszawski J, Mandelbrot L, et al. Is intrapartum intravenous zidovudine for prevention of mother-to-child HIV-1 transmission still useful in the combination antiretroviral therapy era? Clin Infect Dis. 2013;57(6):903–914.
   PubMed Web of Science ®Google Scholar
• Cotter AM, Brookfield KF, Duthely LM, et al. Duration of membrane rupture and risk of perinatal transmission of HIV-1 in the era of combination antiretroviral therapy. Am J Obstet Gynecol. 2012;207(6):482.e1–482.e5.
   Web of Science ®Google Scholar
• Chiappini E, Galli L, Giaquinto C, et al. Use of combination neonatal prophylaxis for the prevention of mother-to-child transmission of HIV infection in European high-risk infants. AIDS. 2013;27(6):991–1000.
   PubMed Web of Science ®Google Scholar
• Wong VV. Is peripartum zidovudine absolutely necessary for patients with a viral load less than 1,000 copies/ml? J Obstet Gynaecol. 2011;31(8):740–742.
   PubMedGoogle Scholar
• Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. [cited 2019 Feb 10]; Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf
   Google Scholar
• Rahangdale L, Cates J, Potter J, et al. Integrase inhibitors in late pregnancy and rapid HIV viral load reduction. Am J Obstet Gynecol. 2016;214(3):385.e1–385.e7.
   Web of Science ®Google Scholar
• Ryom L, Boesecke C, Bracchi M, et al. Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0. HIV Med. 2018;19(5):309–315.
   PubMed Web of Science ®Google Scholar
• Fowler MG, Qin M, Fiscus SA, et al. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med. 2016;375(18):1726–1737.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services; 2019. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Section accessed February 10, 2019.
   Google Scholar
• American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122–1131.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management (NICE Clinical Guideline 107); 2010 [cited 2019 Feb 12]. Available from: https://nice.org.uk/guidance/cg107
   Google Scholar
• Landon MB, Gabbe SG. Gestational diabetes mellitus. Obstet Gynecol. 2011;118(6):1379–1393.
   PubMed Web of Science ®Google Scholar
• Duryea EL, Hawkins JS, McIntire DD, et al. A revised birth weight reference for the United States. Obstet Gynecol. 2014;124(1):16–22.
   PubMed Web of Science ®Google Scholar
• Katz IT, Shapiro R, Li D, et al. Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the Women and Infants Transmission Study. J Acquir Immune Defic Syndr. 2010;54(1):27–34.
   PubMed Web of Science ®Google Scholar
• Cohen J. Things I have learned (so far). Am Psychol. 1990;45(12):1304–1312.
   Web of Science ®Google Scholar
• Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the international antiviral society-USA panel. JAMA. 2016;316(2):191–210.
   PubMed Web of Science ®Google Scholar
• Badell ML, Sheth AN, Momplaisir F, et al. A multicenter analysis of elvitegravir use during pregnancy on HIV viral suppression and perinatal outcomes. Open Forum Infect Dis. 2019;6(4):ofz129.
   PubMed Web of Science ®Google Scholar
• Boucoiran I, Albert AYK, Tulloch K, et al. Human immunodeficiency virus viral load rebound near delivery in previously suppressed, combination antiretroviral therapy-treated pregnant women. Obstet Gynecol. 2017;130(3):497–501.
   PubMed Web of Science ®Google Scholar
• Arab K, Spence AR, Czuzoj-Shulman N, et al. Pregnancy outcomes in HIV-positive women: a retrospective cohort study. Arch Gynecol Obstet. 2017;295(3):599–606.
   PubMed Web of Science ®Google Scholar
• Shust GF, Jao J, Rodriguez-Caprio G, et al. Salvage regimens containing darunavir, etravirine, raltegravir, or enfuvirtide in highly treatment-experienced perinatally infected pregnant women. J Pediatr Infect Dis Soc. 2014;3(3):246–250.
   PubMedGoogle Scholar